Pyxis Oncology (PYXS) Assets Average (2021 - 2026)

Pyxis Oncology (PYXS) has reported Assets Average for 6 consecutive years, with $73.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 43.48% year-over-year to $73.2 million in Q2 2026; TTM through Jun 2026 was $73.2 million, a 43.48% decrease from a year earlier, with the FY2025 full-year figure at $124.4 million, down 24.84% from the prior year.
• Assets Average was $73.2 million for Q2 2026 at Pyxis Oncology, down from $98.6 million in the prior quarter.
• Over five years, Assets Average peaked at $266.4 million in Q1 2022 and troughed at $73.2 million in Q2 2026.
• A 5-year average of $179.6 million and a median of $181.0 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average increased 19.71% in 2024 and slumped 44.08% in 2025, its largest moves.
• Over 5 years, Assets Average stood at $217.6 million in 2022, then retreated by 17.2% to $180.2 million in 2023, then dropped by 2.2% to $176.2 million in 2024, then tumbled by 44.08% to $98.6 million in 2025, then slipped by 25.71% to $73.2 million in 2026.
• The last three Assets Average figures came in at $73.2 million (Q2 2026), $98.6 million (Q4 2025), and $114.4 million (Q3 2025), per Business Quant data.